GlassScriptPhysician profile
George E Fahy
NPI 1578586798
$13,703.03
in general payments reported to CMS, 2019-2025
22 companies · $4,870 in 2025
The $4,870 reported for 2025 was more than what 91% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,213 · 2020: $1,419 · 2021: $972 · 2022: $93.61 · 2023: $207 · 2024: $1,929 · 2025: $4,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $2,213 · Food and Beverage: $1,784 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $2,213.21 |
| Food and Beverage | $1,783.97 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,175.10 | 2024-2025 | |
| Duchesnay USA Incorporated | $3,803.58 | 2019 | |
| Coloplast Corp | $1,965.92 | 2019-2021 | |
| Medtronic, INC. | $688.30 | 2023-2025 | Interstim, Ligasure, Kyphon Express II Kyphopak Tray |
| Medtronic USA, INC. | $337.33 | 2020 | |
| Boston Scientific Corporation | $138.54 | 2019-2020 | |
| Therapeuticsmd, INC. | $90.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $73.87 | 2020-2025 | Aptima |
| Pfizer INC. | $73.44 | 2020-2022 | |
| Abbvie INC. | $72.89 | 2019-2020 | |
| Ethicon US, LLC | $44.03 | 2019-2023 | Surgicel Nu-Knit, Surgiflo Hemostatic Matrix, Enseal |
| Astellas Pharma US INC | $39.91 | 2019 | |
| Axonics, INC. | $34.86 | 2022-2024 | Axonics |
| Amag Pharmaceuticals, INC. | $30.12 | 2019 | |
| Lupin INC. | $26.74 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $25.85 | 2022 | |
| Sanofi Pasteur INC. | $21.23 | 2025 | |
| Millicent US INC | $18.68 | 2024 | Intrarosa |
| Sumitomo Pharma America, INC. | $16.04 | 2024 | Gemtesa |
| Caldera Medical, INC | $13.26 | 2023 | Desara |
| Meditrina | $12.39 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$120,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Fahy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.